SCHEMBL5136107

SCHEMBL5136107

O=C(c1ccccc1-c1ccccc1)N(Cc1ccccc1)C1CCc2ccccc2C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ALDH1A1 P00352 1/20 0.51
KCNH2 Q12809 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
MC4R P32245 2/20 0.44
MC5R P33032 2/20 0.44
DRD3 P35462 1/20 0.42
LTB4R2 Q9NPC1 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MC3R P41968 1/20 0.41
HTR1A P08908 4/20 0.41
HTR7 P34969 4/20 0.41
TACR1 P25103 1/20 0.41
AGER Q15109 3/20 0.40
MTNR1A P48039 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM3 P20309 1/20 0.40
HTR2C P28335 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137387 0.92 MEN1 (0.57) MEN1KMT2AALDH1A1KCNH2SLC6A2
SCHEMBL5136654 0.85 MEN1 (0.49) MEN1KMT2AALDH1A1KCNH2SLC6A2
SCHEMBL5138006 0.84 ALDH1A1 (0.50) MEN1KMT2AALDH1A1KCNH2SLC6A2
SCHEMBL5135771 0.84 MEN1 (0.51) MEN1KMT2AALDH1A1KCNH2SLC6A2
SCHEMBL5359589 0.84 MEN1 (0.51) MEN1KMT2AALDH1A1KCNH2SLC6A2
SCHEMBL5134903 0.82 MTTP (0.50) MEN1KMT2AALDH1A1LTB4R2TACR1
SCHEMBL5136027 0.81 MEN1 (0.51) MEN1KMT2AALDH1A1KCNH2SLC6A2
SCHEMBL6152464 0.81 MEN1 (0.51) MEN1KMT2AALDH1A1KCNH2SLC6A2
SCHEMBL5995268 0.81 OPRM1 (0.48) MEN1KMT2AALDH1A1KCNH2SLC6A2
SCHEMBL5137467 0.81 KMT2A (0.48) MEN1KMT2AALDH1A1KCNH2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed